7498 Results (Page 45 of 300)
Pharmaceuticals Markets Research Reports
Brazil HIV Drugs Market Analysis
Brazil HIV Drugs Market is at around $0.79 Bn in 2023 and is projected to reach $1.09 Bn in 2030, exhibiting a CAGR of 4.6% during the forecast period. The market is expanding due to factors such as the high prevalence of HIV/ AIDS, government initiatives and healthcare policies, and rising spending on healthcare. The market is dominated by key players like Oswaldo Cruz Foundation (Fiocruz), Biolab Sanus, Gilead Sciences, ViiV Healthcare, Boehringer Ingelheim International GmbH, Janssen Pharmaceuticals, Merck & Co., Bristol-Myers Squibb, AbbVie Inc., and F. Hoffman-La Roche Ltd.
UAE HIV Drugs Market Analysis
UAE HIV Drugs Market is at around $0.16 Bn in 2023 and is projected to reach $0.22 Bn in 2030, exhibiting a CAGR of 4.6% during the forecast period. Factors including improvements in drug development, rising healthcare costs, and migration and tourism are driving the market. The market is dominated by key players like Julphar, Neopharma, Gilead Sciences, ViiV Healthcare, Boehringer Ingelheim International GmbH, Janssen Pharmaceuticals, Merck & Co., Bristol-Myers Squibb, AbbVie Inc., and F. Hoffman-La Roche Ltd.
Canada HIV Drugs Market Analysis
Canada HIV Drugs Market is at around $2.54 Bn in 2023 and is projected to reach $3.25 Bn in 2030, exhibiting a CAGR of 3.6% during the forecast period. The market is growing due to the prevalence of HIV/ AIDS, government initiatives and funding, and advancements in drug therapies. The market is dominated by key players like ViiV Healthcare, Gilead Sciences, Boehringer Ingelheim International GmbH, Janssen Pharmaceuticals, Merck & Co., Bristol-Myers Squibb, AbbVie Inc., F. Hoffman-La Roche Ltd., Cipla, Teva Pharmaceutical Industries Ltd., and Johnson & Johnson.
France HIV Drugs Market Analysis
France HIV Drugs Market is at around $0.87 Bn in 2023 and is projected to reach $1.04 Bn in 2030, exhibiting a CAGR of 2.6% during the forecast period. The market is being influenced by factors such as increased HIV incidence, government initiatives, and technological improvements. The market is dominated by key players like Gilead Sciences, ViiV Healthcare, Boehringer Ingelheim International GmbH, Janssen Pharmaceuticals, Merck & Co., Bristol-Myers Squibb, AbbVie Inc., F. Hoffman-La Roche Ltd, Mylan, and Cipla.
US HIV Drugs Market Analysis
US HIV Drugs Market is at around $13.31 Bn in 2023 and is projected to reach $14.88 Bn in 2030, exhibiting a CAGR of 1.6% during the forecast period. The market is driven by rising HIV prevalence, improvements in drug development, and increased testing and awareness campaigns. The market is dominated by key players like Gilead Sciences, ViiV Healthcare, Boehringer Ingelheim International GmbH, Janssen Pharmaceuticals, Merck & Co., Bristol-Myers Squibb, AbbVie Inc., F. Hoffman-La Roche Ltd., Cipla, Teva Pharmaceutical Industries Ltd., and Johnson & Johnson.
South Africa Antifungal Drugs Market Analysis
South Africa Antifungal Drugs Market is at around $0.103 Bn in 2023 and is projected to reach $0.145 Bn in 2030, exhibiting a CAGR of 5.03% during the forecast period. The HIV/AIDS Epidemic, rising fungus infections, government initiatives, and healthcare spending are fueling the market's expansion. The market is dominated by key players like Aspen Pharmacare Holdings Limited, Abbott Laboratories, GlaxoSmithKline plc, Pfizer Inc., Merck & Co., Novartis AG, Astellas Pharma Inc., Sanofi S.A., Bayer AG, Glenmark Pharmaceuticals Limited, and Gilead Sciences Inc.
Kenya Antifungal Drugs Market Analysis
Kenya Antifungal Drugs Market is at around $0.011 Bn in 2023 and is projected to reach $0.015 Bn in 2030, exhibiting a CAGR of 4.9% during the forecast period. The market is expanding due to the high prevalence of HIV/AIDS, technological advancements, and an aging population. The market is dominated by key players like Abbott Laboratories, GlaxoSmithKline plc, Pfizer Inc., Merck & Co., Novartis AG, Astellas Pharma Inc., Sanofi S.A., Bayer AG, Glenmark Pharmaceuticals Limited, and Gilead Sciences Inc.
Egypt Antifungal Drugs Market Analysis
Egypt Antifungal Drugs Market is at around $0.04 Bn in 2023 and is projected to reach $0.06 Bn in 2030, exhibiting a CAGR of 5.3% during the forecast period. The market is driven by rising rates of fungal infections, the growth of the pharmaceutical industry, and government initiatives and policies. The market is dominated by key players like GlaxoSmithKline plc, Pfizer Inc., Merck & Co., Novartis AG, Abbott Laboratories, Astellas Pharma Inc., Sanofi S.A., Bayer AG, Glenmark Pharmaceuticals Limited, and Gilead Sciences Inc.
Vietnam Antifungal Drugs Market Analysis
Vietnam Antifungal Drugs Market is at around $0.07 Bn in 2023 and is projected to reach $0.01 Bn in 2030, exhibiting a CAGR of 4.03% during the forecast period. The market is expanding due to factors like changing lifestyles and urbanization, improvements in healthcare infrastructure, and increased public awareness of fungal infections. The market is dominated by key players like Sanofi-Aventis, Pfizer Inc., Merck & Co., Novartis AG, Abbott Laboratories, Astellas Pharma Inc., GlaxoSmithKline plc, Bayer AG, Glenmark Pharmaceuticals Limited, and Gilead Sciences Inc.
Singapore Antifungal Drugs Market Analysis
Singapore Antifungal Drugs Market is at around $0.019 Bn in 2023 and is projected to reach $0.026 Bn in 2030, exhibiting a CAGR of 4.4% during the forecast period. The market is expanding due to rising awareness and education, advancements in healthcare infrastructure, and an increase in the incidence of fungal infections. The market is dominated by key players like Pfizer Inc., Merck & Co., Novartis AG, Abbott Laboratories, Astellas Pharma Inc., GlaxoSmithKline plc, Bayer AG, Glenmark Pharmaceuticals Limited, Sanofi S.A., and Gilead Sciences Inc.
Philippines Antifungal Drugs Market Analysis
Philippines Antifungal Drugs Market is at around $0.03 Bn in 2023 and is projected to reach $0.4 Bn in 2030, exhibiting a CAGR of 4.3% during the forecast period. The market is driven by factors such as aging populations and immunocompromised patients, growing awareness and education, and advancements in healthcare infrastructure. The market is dominated by key players like United Laboratories Inc., Merck & Co., Pfizer Inc., Novartis AG, Abbott Laboratories, Astellas Pharma Inc., GlaxoSmithKline plc, Bayer AG, Glenmark Pharmaceuticals Limited, Sanofi S.A., and Gilead Sciences Inc.
Japan Antifungal Drugs Market Analysis
Japan Antifungal Drugs Market is at around $0.98 Bn in 2023 and is projected to reach $1.33 Bn in 2030, exhibiting a CAGR of 4.3% during the forecast period. The market is expanding due to rising healthcare costs, the prevalence of risk factors, and technological advancements. The market is dominated by key players like Merck & Co., Pfizer Inc., Novartis AG, Abbott Laboratories, Astellas Pharma Inc., GlaxoSmithKline plc, Bayer AG, Glenmark Pharmaceuticals Limited, Sanofi S.A., and Gilead Sciences Inc.
Malaysia Antifungal Drugs Market Analysis
Malaysia Antifungal Drugs Market is at around $0.025 Bn in 2023 and is projected to reach $0.033 Bn in 2030, exhibiting a CAGR of 4% during the forecast period. The market is being driven by rising rates of fungal infections, rising healthcare costs, and improvements in healthcare infrastructure. The market is dominated by key players like Pharmaniaga Bhd., Duipharma Biotech Bhd., Pfizer Inc., Novartis AG, Merck & Co., Inc., Abbott Laboratories, Astellas Pharma Inc., GlaxoSmithKline plc, Bayer AG, Glenmark Pharmaceuticals Limited, Sanofi S.A., and Gilead Sciences Inc.
Indonesia Antifungal Drugs Market Analysis
Indonesia Antifungal Drugs Market is at around $0.09 Bn in 2023 and is projected to reach $0.12 Bn in 2030, exhibiting a CAGR of 3.8% during the forecast period. The industry is driven by rising healthcare spending, rising awareness and education, and technological advancements. The market is dominated by key players like Pfizer Inc., Novartis AG, Merck & Co., Inc., Abbott Laboratories, Astellas Pharma Inc., GlaxoSmithKline plc, Bayer AG, Glenmark Pharmaceuticals Limited, Sanofi S.A., and Gilead Sciences Inc.
China Antifungal Drugs Market Analysis
China Antifungal Drugs Market is at around $1.3 Bn in 2023 and is projected to reach $1.8 Bn in 2030, exhibiting a CAGR of 5.3% during the forecast period. The factors propelling the market's expansion include government initiatives and healthcare policies, enhanced diagnosis and awareness, epidemiological shifts, and antifungal resistance. The market is dominated by key players like Novartis AG, Merck & Co., Inc., Pfizer Inc., Abbott Laboratories, Astellas Pharma Inc., GlaxoSmithKline plc, Bayer AG, Glenmark Pharmaceuticals Limited, Sanofi S.A., and Gilead Sciences Inc.
UK Antifungal Drugs Market Analysis
UK Antifungal Drugs Market is at around $0.4 Bn in 2023 and is projected to reach $0.5 Bn in 2030, exhibiting a CAGR of 1.8% during the forecast period. The rise in the market is being driven by the rising prevalence of fungal infections, improvements in healthcare infrastructure, and technological advancements in drug development. The market is dominated by key players like Merck & Co., Inc., Pfizer Inc., Abbott Laboratories, Astellas Pharma Inc., GlaxoSmithKline plc, Bayer AG, Novartis AG, Glenmark Pharmaceuticals Limited, Sanofi S.A., and Gilead Sciences Inc.
Spain Antifungal Drugs Market Analysis
Spain Antifungal Drugs Market is at around $0.31 Bn in 2023 and is projected to reach $0.4 Bn in 2030, exhibiting a CAGR of 2.8% during the forecast period. The industry is being driven by the aging population, rising awareness and education, and medical technology advancements in the field. The market is dominated by key players like Merck & Co., Inc., Pfizer Inc., Abbott Laboratories, Astellas Pharma Inc., GlaxoSmithKline plc, Bayer AG, Novartis AG, Glenmark Pharmaceuticals Limited, Sanofi S.A., and Gilead Sciences Inc.
Germany Antifungal Drugs Market Analysis
Germany Antifungal Drugs Market is at around $0.57 Bn in 2023 and is projected to reach $0.67 Bn in 2030, exhibiting a CAGR of 2% during the forecast period. Factors like growing antifungal resistance, increasing R&D activities, and increasing incidence of fungal infections are driving the market. The market is dominated by key players like Pfizer Inc., Abbott Laboratories, Merck & Co., Inc., Astellas Pharma Inc., GlaxoSmithKline plc, Bayer AG, Novartis AG, Glenmark Pharmaceuticals Limited, Sanofi S.A., and Gilead Sciences Inc.
France Antifungal Drugs Market Analysis
France Antifungal Drugs Market is at around $0.43 Bn in 2023 and is projected to reach $0.53 Bn in 2030, exhibiting a CAGR of 2.8% during the forecast period. The market is expanding due to factors such as rising awareness and education, advancements in healthcare infrastructure, and an increase in the incidence of fungal infections. The market is dominated by key players like Pfizer Inc., Abbott Laboratories, Merck & Co., Inc., Astellas Pharma Inc., GlaxoSmithKline plc, Bayer AG, Novartis AG, Glenmark Pharmaceuticals Limited, Sanofi S.A., and Gilead Sciences Inc.
Mexico Antifungal Drugs Market Analysis
Mexico Antifungal Drugs Market is at around $0.2 Bn in 2023 and is projected to reach $0.3 Bn in 2030, exhibiting a CAGR of 4.05% during the forecast period. The market is being driven by innovations and developments in drugs, awareness, and education about fungal infections, and healthcare infrastructure. The market is dominated by key players like Abbott Laboratories, Merck & Co., Inc., Astellas Pharma Inc., Pfizer Inc., GlaxoSmithKline plc, Bayer AG, Novartis AG, Glenmark Pharmaceuticals Limited, Sanofi S.A., and Gilead Sciences Inc.
Brazil Antifungal Drugs Market Analysis
Brazil Antifungal Drugs Market is at around $0.4 Bn in 2023 and is projected to reach $0.55 Bn in 2030, exhibiting a CAGR of 4.8% during the forecast period. The market is expanding as a result of rising fungal infections, improvements in healthcare infrastructure, and the development of antifungal drugs. The market is dominated by key players like EMS Farmaceutia S.A., Abbott Laboratories, Merck & Co., Inc., Astellas Pharma Inc., Pfizer Inc., GlaxoSmithKline plc, Bayer AG, Novartis AG, Glenmark Pharmaceuticals Limited, Sanofi S.A., and Gilead Sciences Inc.
UAE Antifungal Drugs Market Analysis
UAE Antifungal Drugs Market is at around $0.07 Bn in 2023 and is projected to reach $0.1 Bn in 2030, exhibiting a CAGR of 4.8% during the forecast period. The market is expanding due to factors such as the prevalence of fungal infections, improvements in healthcare infrastructure, and technological advancements in drug development. The market is dominated by key players like Neopharma, Abbott Laboratories, Merck & Co., Inc., Astellas Pharma Inc., Pfizer Inc., GlaxoSmithKline plc, Bayer AG, Novartis AG, Glenmark Pharmaceuticals Limited, Sanofi S.A., and Gilead Sciences Inc.
Saudi Arabia Antifungal Drugs Market Analysis
Saudi Arabia Antifungal Drugs Market is at around $0.27 Bn in 2023 and is projected to reach $0.39 Bn in 2030, exhibiting a CAGR of 5.3% during the forecast period. Government initiatives, healthcare infrastructure, and awareness and education regarding fungal diseases are the factors propelling the market's growth. The market is dominated by key players like Abbott Laboratories, Merck & Co., Inc., Astellas Pharma Inc., Pfizer Inc., GlaxoSmithKline plc, Bayer AG, Novartis AG, Glenmark Pharmaceuticals Limited, Sanofi S.A., and Gilead Sciences Inc.
US Antifungal Drugs Market Analysis
US Antifungal Drugs Market is at around $6.64 Bn in 2023 and is projected to reach $7.52 Bn in 2030, exhibiting a CAGR of 1.8% during the forecast period. The market is being driven by rising rates of fungal infections, improvements in drug development, and increase in antifungal resistance. The market is dominated by key players like Pfizer Inc., Merck & Co., Inc., Astellas Pharma Inc., Abbott Laboratories, GlaxoSmithKline plc, Bayer AG, Novartis AG, Glenmark Pharmaceuticals Limited, Sanofi, and Enzon Pharmaceuticals, Inc.
Canada Antifungal Drugs Market Analysis
Canada Antifungal Drugs Market is at around $1.3 Bn in 2023 and is projected to reach $1.6 Bn in 2030, exhibiting a CAGR of 3.8% during the forecast period. The market is growing due to the prevalence of fungal infections, consumer awareness and education, and partnerships and collaborations. The market is dominated by key players like Apotex Inc., Paladin Labs Inc., Abbott Laboratories, Merck & Co., Inc., Astellas Pharma Inc., Pfizer Inc., GlaxoSmithKline plc, Bayer AG, Novartis AG, and Glenmark Pharmaceuticals Limited.
